Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2018/2019 influenza season

as of September 09, 2019

|                            | по и осрешного,       |                        |                        |           |             |               |            |             |           |           |             |               |           |             |           |           |             |
|----------------------------|-----------------------|------------------------|------------------------|-----------|-------------|---------------|------------|-------------|-----------|-----------|-------------|---------------|-----------|-------------|-----------|-----------|-------------|
|                            |                       |                        |                        |           | A(H3N2)     |               |            |             |           |           | В           |               |           |             |           |           |             |
|                            | Baloxavir             | Oseltamivir            | Peramivir              | Zanamivir | Laninamivir | Amantadine    | Baloxavir  | Oseltamivir | Peramivir | Zanamivir | Laninamivir | Amantadine    | Baloxavir | Oseltamivir | Peramivir | Zanamivir | Laninamivir |
| Resistant (%)              | 6 <sup>a</sup> (1.8%) | 17 <sup>b</sup> (0.8%) | 17 <sup>b</sup> (0.8%) | 0         | 0           | 188<br>(100%) | 34° (9.6%) | 0           | 0         | 0         | 0           | 155<br>(100%) | 0         | 0           | 0         | 0         | 0           |
| Number of viruses tested   | 330                   | 2,099                  | 2,099                  | 316       | 316         | 188           | 356        | 322         | 322       | 322       | 322         | 155           | 40        | 95          | 95        | 95        | 95          |
| Number of viruses reported | 2,979                 |                        |                        |           |             |               | 4,601      |             |           |           |             |               | 567       |             |           |           |             |

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>&</sup>lt;sup>a</sup> Patients without treatment 0

<sup>&</sup>lt;sup>b</sup> Patients without treatment 4

<sup>&</sup>lt;sup>c</sup> Patients without treatment 5